A multicenter, international, non-controlled, phase II trial to identify the molecular mechanisms of resistance and sensitivity to palbociclib re-challenge upon progression to a palbociclib combination in ER-positive metastatic breast cancer patients (BioPER). Code: MedOPP089.
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Palbociclib (Primary)
- Indications Advanced breast cancer
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms BioPER
- Sponsors Medica Scientia Innovation Research
- 31 Aug 2018 Biomarkers information updated
- 28 Aug 2017 Status changed from not yet recruiting to recruiting.
- 29 Mar 2017 New trial record